News | Pacemakers | August 09, 2021

Boston Scientific Recalls INGENIO Family of Pacemakers

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death

August 9, 2021 — Boston Scientific is recalling INGENIO family of pacemakers and CRT-Ps due to the risk of incorrect transition to safety mode. Safety mode is intended to provide backup if the device is faulty. However, in safety mode, there is a risk of inappropriate loss of pacing due to sensing of muscle contractions. If the device incorrectly goes into safety mode, the device cannot be reprogrammed and must be replaced.

The use of affected product may cause serious adverse health consequences, including early device replacement, loss of pacing or ability to regulate heart rate with serious or life threatening injury (for example, need of temporary pacing where a healthcare provider delivers controlled electric pulses to pace a heart), worsening of heart failure and death.

There have been 65 reported incidents, including three injuries which required patients to receive temporary external pacing. There have been no reports of death.

Who May be Affected

  • Health care providers using affected Boston Scientific Recall of INGENIO family of pacemakers and CRT-Ps
  • Patients implanted with affected devices

What to Do

On June 3, 2021, Boston Scientific sent all affected customers an Important Medical Device Advisory. The letter requested customers to:

  • When assessing potential risk for a patient if their device incorrectly transitions to safety mode, consider patient-specific factors (which may vary over time), including underlying health issues, pacemaker dependence, or problems with pacing.
  • If a device incorrectly enters safety mode, schedule replacement. Boston Scientific does not recommend preventive replacement for affected devices. However, for individual patients, factors such as those listed above in the previous bullet and shared decision-making may support consideration of early device replacement to prevent unintended outcomes. In these cases, the following guidance should be considered:
    • For EL pacemakers, if early replacement is planned, schedule replacement when the service life of the device is four years (or less, if the device currently indicates fewer than four years remaining).
    • For CRT-Ps, if early replacement is planned, schedule replacement when the service life of the device remaining is three years (or less, if the device currently indicates fewer than three years remaining).
  • Perform a system follow-up remotely or in person at least every 12 months. For patients who may not require early device replacement, continue with existing follow-up procedures until there is one year of service life expected and then follow-up every three months until replacement (as indicated in the device’s instructions for use).
  • For each patient with an affected device, add the Boston Scientific INGENIO EL Pacemakers and CRT-Ps Physician Letter sent on June 3, 2021 to their medical record to maintain awareness of this topic for the remaining service life of the device.
  • Report adverse events experienced with the INGENIO family of pacemakers or CRT-Ps to Boston Scientific or the FDA’s MedWatch Adverse Event Reporting program.
  • Return explanted devices to Boston Scientific. A no-cost Return Product Kit is available from your local Boston Scientific representative. This kit is also available at no charge through Boston Scientific's Customer Service department at 1-800-CARDIAC (227-3422) or 651-582-2698.

For more information: www.bostonscientific.com


Related Content

News | Pacemakers

March 26, 2024 — UC San Diego Health is the first health system in San Diego to successfully implant the world’s first ...

Home March 26, 2024
Home
News | Pacemakers

March 15, 2024 — Following the recent CE approval of the Solia S lead1 for LBBAP, BIOTRONIK proudly announces the world ...

Home March 15, 2024
Home
News | Pacemakers

March 15, 2024 — Following the recent CE approval of the Solia S lead1 for LBBAP, Biotronik announces the world’s first ...

Home March 15, 2024
Home
News | Pacemakers

January 5, 2024 — Medtronic, a global leader in healthcare technology, today announced it has received CE (Conformité ...

Home January 05, 2024
Home
News | Pacemakers

August 21, 2023 — The first implant in Europe of Biotronik’s latest pacemaker and CRT-P generation was conducted in ...

Home August 21, 2023
Home
News | Pacemakers

July 6, 2023 — BIOTRONIK announced U.S. Food and Drug Administration (FDA) approval of its portfolio of Amvia Edge ...

Home July 06, 2023
Home
News | Pacemakers

July 5, 2023 — Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the AVEIR dual chamber (DR ...

Home July 05, 2023
Home
News | Pacemakers

June 1, 2023 — Every year more than one million people receive a pacemaker. Until now, leadless versions were only ...

Home June 01, 2023
Home
News | Pacemakers

May 25, 2023 — Abbott announced late-breaking results from the AVEIR dual-chamber (DR) i2i Investigational Device ...

Home May 25, 2023
Home
News | Pacemakers

May 12, 2023 — Biotronik, a leading global medical technology company with 60 years of experience in developing trusted ...

Home May 12, 2023
Home
Subscribe Now